M&A Corner
Aldena Raises $30M To Advance Skin-Deep siRNA Therapies20 Mar 2023
Aldena Therapeutics has raised $30 million from investment firm Medicxi. The funds will help the Boston-based biotech accelerate the development... Continue Reading
|
Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering20 Mar 2023
Dermata Therapeutics, Inc. (“Dermata,” or the “Company”) (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and... Continue Reading
|
Seamless Therapeutics Launches With $12.5M Seed Financing To Advance Transformative Gene Editing Platform Based On Programmable Precision Designer Recombinases20 Mar 2023
Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases,... Continue Reading
|
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-In-Class Fibrosis Therapies20 Mar 2023
Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt and even reverse the course of... Continue Reading
|
Shennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery With Proprietary Single-Cell Functional Screening Platform20 Mar 2023
Shennon Biotechnologies (“ShennonBio”), a biotech company using a proprietary single cell platform to create more effective immunotherapies, announced today the... Continue Reading
|
Pfizer Acquires Seagen For $43B To Tackle Cancer20 Mar 2023
What You Should Know: Pfizer announced it will acquire biotechnology company Seagen for $229 per Seagen share in cash, for... Continue Reading
|
Acasti Pharma Inc. Centralizes Marketplace For Shares On The Nasdaq With Voluntary Delisting from TSX Venture Exchange20 Mar 2023
Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical... Continue Reading
|
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank20 Mar 2023
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today reassured its shareholders... Continue Reading
|
Price Cap Move Will Help Eli Lilly Remain Dominant Player in Insulin Market, Says GlobalData20 Mar 2023
GlobalData, a data and analytics company, on Monday said that it is likely that Lilly will remain a leading manufacturer... Continue Reading
|
Sanofi Bolsters Diabetes Position With $2.9B Provention Buyout20 Mar 2023
Sanofi will acquire diabetes leader Provention Bio for $25 per share, adding up to a total of $2.9 billion, the... Continue Reading
|